NKILA inhibition in tumor-infiltrating lymphocytes and CAR T cells may silence their activation-induced cell death, thus suppressing tumor immune evasion and expanding the efficacy of cancer immunotherapy [144]. The gene discussed is NKILA; the disease is neoplasm.